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Aims Circulating adiponectin (APN) is an immunomodulatory, pro-angiogenic, and anti-apoptotic adipocytokine protecting
against acute viral heart disease and preventing pathological remodelling after cardiac injury. The purpose of this study
was to describe the regulation and effects of APN in patients with inflammatory cardiomyopathy (DCMi).
Methods
and results
Adiponectin expression and outcome were assessed in 173 patients with DCMi, 30 patients with non-inflammatory
DCM, and 30 controls. Mechanistic background of these findings was addressed in murine experimental autoimmune
myocarditis (EAM), a model of human DCMi, and further elucidated in vitro. Adiponectin plasma concentrations were
significantly higher in DCMi compared with DCM or controls, i.e. 6.8+ 3.9 mg/mL vs. 5.4+ 3.6 vs. 4.76+ 2.5 mg/mL
(P, 0.05, respectively) and correlated significantly with cardiac mononuclear infiltrates (CD3+: r2¼ 0.025,
P ¼ 0.038; CD45R0+: r2¼ 0.058, P ¼ 0.018). At follow-up, DCMi patients with high APN levels showed significantly
increased left ventricular ejection fraction improvement, decreased left ventricular end-diastolic diameter, and
reduced cardiac inflammatory infiltrates compared with patients with low APN levels. A multivariate linear regression
analysis implicated APN as an independent prognostic factor for inhibition of cardiac inflammation. In accordance
with these findings in human DCMi, EAM mice exhibited elevated plasma APN. Adiponectin gene transfer led to sig-
nificant downregulation of key inflammatory mediators promoting disease. Mechanistically, APN acted as a negative
regulator of T cells by reducing antigen specific expansion (P, 0.01) and suppressed TNFa-mediated NFkB acti-
vation (P, 0.01) as well as release of reactive oxygen species in cardiomyocytes.
Conclusion Our results implicate that APN acts as endogenously upregulated anti-inflammatory cytokine confining cardiac inflam-
mation and progression in DCMi.
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Introduction
Adiponectin (APN), a 30 kDa adipocytokine, is constitutively
present in high concentrations in human plasma as a low molecular
weight (LMW), a middle molecular weight (MMW), and a high
molecular weight (HMW) form. Adiponectin is mainly produced
by adipose tissue but cardiomyocytes are also capable of
synthesizing APN and express its receptors, APN receptor 1
(APN-R1) and APN receptor 2 (APN-R2).1,2 Adiponectin exhibits
immunomodulatory, anti-proliferative, anti-apoptotic, and
pro-angiogenic effects and APN plasma concentrations are inver-
sely correlated with classical cardiovascular risk factors such as
body mass index (BMI),3 hypertension, and diabetes. In animal
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studies, APN inhibited cardiac remodelling following aortic banding
and myocardial infarction.4,5
Low concentrations of APN in humans have been associated
with the increased risk of incident coronary heart disease in
healthy participants.6 High concentrations of APN have been
associated with increased disease severity and adverse outcomes
in patients with established heart failure, and possibly result from
the cachexia observed in more advanced disease stages.7 –9
Although one cross-sectional study showed APN concentrations
to be greater in patients with heart failure compared with controls,
a prospective cohort study of elderly Swedish men and a recently
published trial of the Framingham Offspring Study failed to detect
an association between APN concentrations and heart failure inci-
dence.10 Therefore, the contradicting observations of APNs’ cardi-
ovascular effects clearly need further elucidation.
Inflammatory cardiomyopathy (DCMi) is frequently caused by
viral infection that has been implicated as an important causal
factor responsible for the progression to dilated cardiomyopathy.
Viral infection triggers an inflammatory process, i.e. by expression
of cytokines, chemokines, and abundant infiltration with T cells and
macrophages that outlasts the initial replicative phase and may lead
to postviral autoimmunity. Chronic inflammation leads to tissue
injury, endothelial dysfunction, and cardiac remodelling resulting
in deterioration of myocardial contractility and left ventricular ejec-
tion fraction (LVEF). Therefore, the immune response character-
ized by immunohistologically proven inflammatory infiltrates
plays a crucial role for the outcome of DCMi.11
Adiponectin exerts profound immunomodulatory effects and
modulates cytokine production and phagocytosis of macro-
phages12 as well as cytotoxicity of NK cells.13 Although initially
described as anti-inflammatory cytokine, more recent studies
also reported pro-inflammatory effects.14,15 In this regard, APN
was shown to induce NFkB in vitro, a master transcription factor
for pro-inflammatory cytokines.16 However, most animal studies
provide evidence for an anti-inflammatory role. In a mouse
model of encephalomyocarditis (EMC) virus-induced myocarditis,
impaired expression of cardiac APN contributed to the pro-
gression of viral myocarditis.17 In line with this finding, APN repla-
cement therapy attenuated myocardial damage in leptin-deficient
mice with acute viral myocarditis.18 Furthermore, better survival
of obese KKAy mice with viral myocarditis on a reduced energy
diet correlated with higher cardiac APN expression.19 Moreover,
APN gene transfer ameliorated the degree of chronic inflammation
by promoting the clearance of apoptotic bodies via calreticulin-
dependent phagocytosis in lpr mice with lupus-like autoimmune
disease.20
The effects of APN on inflammation in human DCMi have not
been studied yet. Therefore, we investigated the systemic and
cardiac APN expression of APN, its correlation with haemo-
dynamic and inflammatory parameters in plasma and endomyocar-
dial biopsy (EMB) specimens, and its effects on the outcome in
well-characterized patients with DCMi. In order to extend our
mechanistic insights and corroborate our findings, we performed
additional in vitro and vivo experiments using a mouse model of
experimental autoimmune myocarditis (EAM) that mimics certain
aspects of human DCMi.
Methods
Patients
Two hundred thirty-three consecutive patients who were submitted
with clinical symptoms and signs of heart failure (i.e., dyspnoea and
chest pain, NYHA II-III) underwent right ventricular EMB for histologi-
cal, immunohistological, and molecular virological analysis following
angiographic and echocardiographic exclusion of coronary heart
disease and other possible causes of cardiac dysfunction such as valv-
ular or systemic diseases with cardiac involvement. Endomyocardial
biopsies were assessed for inflammation and viral genomes using stan-
dardized protocols.21 According to the protocol of the study, patients
were divided into a control group, in which the diagnostic workup
finally revealed that their complaints were non-cardiac in origin, a
DCM and a DCMi group. At enrolment, the duration of observed
symptoms was 34+5.65 days. The following criteria defined control
patients: LVEF .60%, left ventricular end-diastolic diameter
(LVEDD) , 55 mm, CD3+ ,7 per mm2, (n ¼ 30); patients with
decreased LVEF ,60%, increased LVEDD .55 mm, and a negative
myocardial inflammation score (CD3+ ,7 per mm2) were included
into a DCM group (n ¼ 30). Inflammatory cardiomyopathy patients
showed LVEF ,60%, LVEDD .55 mm, and CD3 .7 per mm2 (n ¼
173). Inflammatory cardiomyopathy was defined as a cardiomyopathy
with decreased LVEF, increased LVEDD, and a positive myocardial
inflammation score according to the Dallas criteria and criteria of
the World Heart Federation (WHF). Demographic and clinical charac-
teristics of patients are shown in Table 1. A follow-up examination of
all patients in the DCMi group for determination of LVEF by an echo-
cardiographic study was performed 6 months after inclusion into the
study registry. All patients were treated according to the guidelines
for medical treatment of heart failure (Supplementary material
online, Table S1). Moreover, 63 patients with persistent symptoms of
heart failure despite heart failure medication underwent follow-up
EMBs according to the present guidelines.22 The study protocol was
set up in accordance to the ethics principles in the Declaration of
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Table 1 Baseline characteristics of patients
Control,
n5 30
DCM,
n 5 30
DCMi,
n5 173
Sex (m/f) 17/13 27/3 139/34
Age (years) 44.03+12.85 46.72+13.48 51.13+12.92
BMI (kg/m2) 24.3+4.36 26.96+3.96 27.05+4.91a
EF (%) 70.1+8.07 38.57+13.59 31.79+13.55a
LVEDD (mm) 50.61+6.27 59.64+10.05 61.6+10.02a
LVEDP (mmHg) 10.96+3.9 14.8+8.82 14.39+8.78
PAP (mmHg) 12.96+3.8 16.89+8.12 22+11.66a
PC (mmHg) 7.54+3.56 9.58+6.78 12.27+9.03a
CI (L/min/m2) 3.77+0.84 3.39+0.71 2.86+0.7a
CD3+ (n/mm2) 1.33+1.14 1.5+1.06 16.15+9.14a,b
CD45RO (n/mm2) 5.52+2.7 4.42+3.66 21.37+31.22a,b
NYHA II: 14; III: 16 II: 12; III: 18 II: 78; III: 95
Data are presents as mean+ SD.
aDCMi vs. control P, 0.05.
bDCMi vs. DCM P, 0.05.
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Helsinki and was approved by the local ethics committee. Written
informed consent was obtained from all patients.
Haemodynamic measurements and
endomyocardial biopsies
Haemodynamic parameters of each patient were measured as pre-
viously described.21 In brief, function of the left ventricle was studied
by using the AVD system (Angiographic Ventricular DynamicsTM)
and by analysing the mechanical function of the heart by means of
X-ray visualization during contrast injection. The 2-frame routine was
used for calculation of LVEF. Left ventricular end-diastolic pressure
(LVEDP) and capillary pressure (PC) were determined by catheteriza-
tion with a tip catheter and cardiac index (CI) with a flow-directed
catheter. In addition, echocardiography was performed on all patients
to evaluate LVEDD. At least five EMBs were taken from all patients
using a CordisTM bioptom. Biopsies were analysed histologically and
immunohistologically. Viral genomes were detected by polymerase
chain reaction as described previously.21
Figure 1 Adiponectin (APN) expression is elevated in human inflammatory cardiomyopathy (DCMi). (A) Plasma concentrations of APN and
high molecular weight in the control (n ¼ 30), DCM (n ¼ 30), and DCMi (n ¼ 173) groups were measured by ELISA. Data are presented as
mean+ SEM. (B) Cardiac APN mRNA expression and protein expression were determined by QRT–PCR and immunohistochemistry, respect-
ively. Significant differences are marked (#P ¼ 0.011; §P ¼ 0.034). (C) Correlation of cardiac APN mRNA expression with CD3+ positive cell
number in patients with DCMi.
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Histological and immunhistological studies
Formalin fixed and paraffin embedded EMBs were assessed for inflam-
mation and histological characteristics by light microscopy. Immunhis-
tochemical analysis of inflammation [i.e. mononuclear infiltration
(CD3+, MAC-1, LFA, CD45R0) as well as endothelial activation
(ICAM, VCAM, HLA expression)] and cardiac APN expression were
performed as previously described.2,23,24
Measurement of adiponectin and
inflammatory cytokines
To assess total APN, HMW-APN, MMW-APN, and LMW-APN
in human plasma, a specific assay from Immundiagnostik AG
(Bensheim, Germany) was used according to the protocol supplied
by the manufacturer. This system was capable of quantifying total
APN and its different multimers in a single ELISA as described pre-
viously.25 Human soluble TNF-receptor 1 (sTNFR1) and C-reactive
protein were measured by ELISA (R&D Systems). Interleukines 2, 4,
6, 8, and 10 were determined by cytometric bead array (BD
Biosciences).
Animal model of autoimmune myocarditis
To induce EAM, female BALB/c wild-type mice were immunized with
200 mL/mouse of a 1:1 emulsion of PBS with 1 mg/mL of MyHC-a
peptide in CFA at Days 0 and 7. Control mice were immunized
with PBS/CFA only. Replication defective adenoviral vectors expres-
sing mouse APN under the control of a CMV promoter (Ad-APN)
or control vectors (Ad-RR5) were injected intravenously 1 week
before immunization (Day 27). Mice were analysed on Day 21.
Hearts were removed and snap frozen. RNA was extracted by hom-
ogenizing the tissue in Trizol. Mouse cytokines and cytokine receptor
RNA arrays were purchased from SA-Biosciences (Frederick, MD,
USA) and performed as suggested by the manufacturer. For the syn-
thesis of cDNA, the RT2 PCR Array First Strand Synthesis Kit
(SA-Biosciences) was used. Analysis of chemokine and receptor
expression was carried out employing the RT2 Profiler PCR Array
System (SA-Biosciences). For mouse APN measurements, R&D
Systems APN ELISA was employed according to the protocol pro-
vided by the manufacturer. TAQ-Man PCR was performed with
mouse APN (Mm00456425_m1) and mouse APN receptor 1/2
(Mm01291331_m1, Mm01184032_m1), and primer sets were pur-
chased from Applied Biosystems. Evaluation was performed by the
DDCt method.
Characterization of antigen-specific T cell
response
Mononuclear cells were isolated from healthy HLA-A2-positive volun-
teers by Ficoll-Hypaque density gradient centrifugation and were cryo-
preserved until analysis. For T cell expansion, mononuclear cells were
incubated for 12 h without or with APN (3 mg/mL) and transferred
into 96-well round-bottom plate (2 × 105 cells per well) together
with influenza or Epstein-Barr virus (EBV) peptides or HIV peptides,
rhIL-2 (50 IU/mL, R&D Systems), and rhIL-7 (10 ng/mL, R&D
Systems) after APN incubation. Media and IL-2 were changed on
Days 3 and 5. IL-7 was added after 1 week. After 10 days of culture,
cells were harvested, washed, and evaluated for specific T cells by
flow cytometry. Antigen-specific T cells were detected by intracellular
cytokine staining after 6 h incubation with either an HLA-A2-binding
influenza peptide or irrelevant HIV peptides as described previously.26
In brief, peripheral blood mononuclear cells (PBMC) (2 × 106) were
incubated with 10 mg/mL of each peptide. After 1 h, 7.5 mg/mL brefel-
din A (Sigma, Deisenhofen, Germany) was added and after another 5 h,
PBMC were surface-stained with fluorescence-conjugated monoclonal
antibodies against CD3 and CD8 and intracellularly against IFN-g, IL-2,
and TNFa following fixation and permeabilization (BD Biosciences).
Data acquisition was performed on a FACS Canto cytometer and ana-
lysed using DIVA Software (BD Bioscience).
NFkB-activation in cardiac myocytes and
fibroblasts
Neonatal rat ventricular myocytes (NRVM) and fibroblasts were iso-
lated and cultured as described previously.2 Cells were then stimulated
with TNFa (20 ng/mL) in the presence or absence of APN (10 mg/mL)
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Table 3 Correlation of adiponectin expression with inflammatory markers in patients with inflammatory
cardiomyopathy (n5 173)
CD31 CD45 RO IL-8 C-reactive
protein
sTNF-R1 LFA1 Mac1
APN 0.025 (P ¼ 0.038) 0.058 (P ¼ 0.018) 0.106 (P ¼ 0.009) 0.145 (P ¼ 0.002) 0.14 (P ¼ 0.003) 0.081 (P ¼ 0.016) 0.056 (P ¼ 0.046)
HMW 0.024 (P ¼ 0.042) 0.079 (P ¼ 0.005) 0.111 (P ¼ 0.007) 0.132 (P ¼ 0.004) 0.184 (P ¼ 0.001) 0.054 (P ¼ 0.051) 0.042 (P ¼ 0.041)
Correlations are presented as r2. HLA1, ICAM, VCAM, IL-2, IL-4, and IL-6 did correlate with plasma APN (data not shown).
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Table 2 Correlations of haemodynamic parameters with adiponectin expression in inflammatory cardiomyopathy
(n 5 173)
EF LVEDD LVEDP PAP PC CI
APN 0.114 (P, 0.001) 0.043 (P ¼ 0.011) 0.01 (P ¼ 0.248) 0.13 (P ¼ 0.004) 0.096 (P ¼ 0.005) 0.266 (P, 0.001)
HMW 0.114 (P, 0.001) 0.028 (P ¼ 0.039) 0.004 (P ¼ 0.447) 0.166 (P ¼ 0.001) 0.081 (P ¼ 0.01) 0.226 (P, 0.001)
Data of correlation are presented as r2. MMW and LMW did not correlate with haemodynamic parameters (data not shown).
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or an NFkB inhibitor (BAY-11-7082, 20 mM, Sigma) for 30 min. Whole
cells were lysed in sample buffer supplied and NFkB activation was
determined by ELISA as described by the manufacturer (ActiveMotifw,
Rixensart, Belgium).
Measurement of intracellular redox stress
Intracellular generation of reactive oxygen species (ROS) was deter-
mined using 2′,7′-dichlorofluorescin diacetate (DCFH-DA), which is
rapidly oxidized to the highly fluorescent 2′,7′-dichlorofluorescin
Figure 2 High adiponectin (APN) expression indicates favourable outcome at follow-up. (A) Inflammatory cardiomyopathy (DCMi) patients
were separated into tertiles depending on their APN plasma concentrations at enrolment. Outcome is expressed as difference of ejection frac-
tion (EF at follow up – EF at enrolment) in the following groups: (1) low adiponectin (n ¼ 58), (2) medium adiponectin (n ¼ 58), (3) high adi-
ponectin (n ¼ 57). (B) Outcome is expressed as difference in LVEDD (LVEDD at follow up – LVEDD at enrolment). (C) Outcome is expressed
as difference in NT-proBNP (NT-proBNP at follow-up – NT-proBNP at enrolment). All data are presented in a box and whiskers appearance
(median, 25% percentile, 75% percentile,+ SD). (D and E) DCM patients were separated into tertiles (n ¼ 10) depending on their APN serum
concentrations at enrolment. Outcome is expressed as difference of ejection fraction (EF at follow up – EF at enrolment) and as difference in
left ventricular end-diastolic diameter (LVEDD) (LVEDD at follow up – LVEDD at enrolment).
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(DCF) in response to ROS production within the cells. Neonatal rat
ventricular myocytes were cultured for 24 h in DMEM+ 10% FBS in
96 wells. Cells were then incubated in DMEM+ 1% FBS with or
without APN (10 mg/mL) for 4 h. After washing in HBSS, cells were
cultured in HBSS and DCFH-DA (DCFH-DA, Sigma) (8.64 mM) and
H2O2 [400 mM, (Merck)] for 120 min. Fluorescence intensity was
quantified every 10 min employing a fluorescence reader (excitation
480 nm, emission 540 nm) at 378C (Molecular Devices).
Statistical analysis
For statistical analysis, SPSS statistical software version 16.0 was used.
All data were expressed as mean+ SD. A value of P, 0.05 was
regarded as statistically significant. A t-test for parametrically distribu-
ted data and a Wilcoxon matched-pair signed rank test for non-
parametrically distributed data were utilized to compare parameters
at the beginning and at the end of the study. Quantitative variables
with normal distribution were analysed with student’s t-test, and vari-
ables without normal distribution with a two-tailed Mann–Whitney
U-test. Correlation analysis was performed with Pearson’s and
Spearman’s test. Correction for Bonferroni was not performed. Multi-
variate linear regression was calculated to analyse the factors indepen-
dently affecting specific variants. An a-error ,5% was considered
statistically significant. Factors such as CD3+ baseline cell numbers,
APN baseline levels, LVEF, BMI, sex, age, C-reactive protein, brain
natriuretic peptide (NT-proBNP), sTNFR1, and LVEDD were included
in our analysis. Non-significant variants were subsequently excluded.
Results
Adiponectin concentrations are elevated
in patients with inflammatory
cardiomyopathy
Patient characteristics for the study groups are shown in Table 1.
As illustrated in Figure 1A, systemic APN concentrations in patients
with DCMi (median: 5.73 mg/mL, 25% percentile: 4.06 mg/mL, 75%
percentile: 8.84 mg/mL) were significantly higher when compared
with DCM patients (median: 4.67 mg/mL, 25% percentile:
2.99 mg/mL, 75% percentile: 6.38 mg/mL) and controls (median:
4.52 mg/mL, 25% percentile: 2.68 mg/mL, 75% percentile: 5.97 mg/
mL). High molecular weight APN concentrations also differed sig-
nificantly. Moreover, cardiac APN mRNA expression in DCMi
(APNmRNA/18sRNA: 0.034+ 0.01 vs. 0.135+0.03, P ¼ 0.011)
and protein expression in DCMi (area fraction: 0.089+0.04 vs.
0.12+ 0.01, P ¼ 0.034) were significantly upregulated (Figure 1B).
Adiponectin concentrations in patients
with inflammatory cardiomyopathy
correlate with cardiac haemodynamics
and inflammation
In order to further investigate factors associated with elevated APN
plasma levels in patients with DCMi, haemodynamics and the
amount of cardiac mononuclear inflammatory infiltrates were ana-
lysed. Plasma APN concentrations were inversely correlated with
LVEF. A similar pattern was observed for HMW-APN. An overview
about correlations of APN levels with invasively measured haemo-
dynamic parameters is depicted in Table 2. Furthermore, APN
plasma concentrations correlated in a significant manner with
CD3+ T cell and CD45R0+ memory T cell number in EMB speci-
mens at time of inclusion into the study (Table 3), while no corre-
lation could be demonstrated between EF and mononuclear
infiltration (r2¼ 0.004, P ¼ 0.433). Those data indicate a relationship
between impairment of cardiac function as well as the extent of
cardiac inflammation with systemic APN concentrations. Further-
more, plasma concentrations of IL-8, soluble sTNFR1, and
C-reactive protein significantly correlated with APN plasma levels,
implicating the inflammatory process in the regulation of APN
(Table 3). In support of this contention, cardiac APN mRNA and
protein expression were upregulated in DCMi and significantly cor-
related with cardiac inflammation (Figure 1B and C ).
High adiponectin serum concentrations
indicate better outcome and reduced
cardiac inflammation at follow-up in
inflammatory cardiomyopathy patients
Patients were evaluated at 6 months follow-up and divided into three
groups according to their baseline APN plasma concentrations. As
illustrated in Figure 2A and Table 4, patients with high APN plasma
levels at baseline exhibited a better improvement in LVEF compared
with patients in the lowest tertile of baseline APN concentrations.
Accordingly, LVEDD significantly improved in patients in the upper
tertile of serum APN compared with patients with lower APN base-
line levels (Figure 2B). In accordance with those functional par-
ameters, NT-proBNP, a marker for prognosis in DCMi, showed a
significant improvement at follow-up in high APN expressing
patients (NT-proBNP: P,0.001; Figure 2C). In contrast, APN
effects on outcome were not observed in DCM patients (Figure 2D
and E). These data suggest that APN expression is associated with
favourable outcome in DCMi patients, and might implicate a protec-
tive effect of the adipocytokine. In fact, analysis of follow-up heart
biopsy specimens (n ¼ 63) revealed an association of high baseline
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 4 Follow-up of inflammatory cardiomyopathy
patients—haemodynamic and inflammatory markers
are shown for tertiles of adiponectin expression (CD3
diff rel: [CD3 diff/CD3 enrolment] 3100)
1, n 5 58 2, n 5 58 3, n5 57
APN (mg/mL) 3.4+0.74 5.8+0.9 11.3+3.3
EF1 (%) 35+14 36+12 26+13
EF2 (%) 45+15 43+13 40+16
EF diff (%) 9+9 6+12 15+13
EF diff rel (%) 35.2+49.5 21.8+41.8 82.7+94.1
LVEDD1 (mm) 60+9.5 60+10.4 65.2+9.3
LVEDD2 (mm) 58+9.3 56+9.4 60+10.0
LVEDD diff (mm) 22.3+5 23.1+5.3 25.4+7.1
LVEDD diff rel (%) 23.7+8.1 24.8+9.4 28+10.9
CD3 diff (n/mm2) 25.7+3.5 28.3+7.9 212.4+13.9
CD3 diff rel (%) 246.4+22.3 247.8+29.4 268.8+15.3
BNP 1 (pg/mL) 576+327 585+360 906+537
BNP 2 (pg/mL) 454+282 444+282 582+437
BNP diff (pg/mL) 2122+215 2138+279 2356+402
Data are presents as mean+ SD. The number of patients in each group for the
values of CD3 is n ¼ 21.
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APN levels with lower numbers of heart infiltrating cells at 6 months.
As shown in Figure 3A, the decrease of CD3+ T cells was most pro-
nounced in patients with high serum APN concentrations (high vs.
low APN: 67+ 17 vs. 47+23%, P ¼ 0.003). In order to address
the question whether APN is an independent prognostic factor for
inflammation in DCMi, a multivariate linear regression analysis was
performed, including CD3+ baseline cell numbers, APN baseline
levels, age (P ¼ 0.76), NT-proBNP (P ¼ 0.78), sTNR-R1 (P ¼
0.83), sex (P ¼ 0.63), BMI (P ¼ 0.53), C-reactive protein (P ¼
0.54), LVEF (P ¼ 0.25), and LVEDD (P ¼ 0.45). Interestingly both
CD3+ baseline cell numbers and APN baseline levels had a con-
siderable impact on the CD3 changes at 6-month follow-up
(CD3diff): as shown in Figure 3B and Table 4, higher systemic APN
concentrations and CD3 cell counts at study entry were associated
with higher CD3diff changes on follow-up. Both parameters alone
accounted for 49% of the variation of CD3diff. Moreover, in line
with lower myocardial inflammation, APN levels were decreased
compared with study inclusion, but still elevated compared with con-
trols and still correlated with cardiac inflammation (Figure 3C and D).
Murine autoimmune myocarditis is
associated with high adiponectin
expression and adiponectin gene transfer
inhibits cardiac inflammation
To further test our hypothesis that APN acts as an anti-
inflammatory cytokine in inflammatory cardiomyopathy and to
corroborate our human data, we used an EAM model, which
Figure 3 High APN expression is associated with diminished cardiac inflammation in the course of inflammatory cardiomyopathy (DCMi). (A)
CD3+ T cells were determined in endomyocardial biopsies by immunohistological staining at enrolment and six month follow up. 63 consecu-
tive DCMi patients were grouped according to their APN serum concentrations (n ¼ 21 in each group). These 3 groups were compared
according to CD3+ cells at baseline and follow-up. Bar graph illustrates relative improvement within these groups. (B) Multivariate linear
regression model for CD3diff (CD3diff: [CD3+ cells at follow-up] – [CD3+ cells at baseline]). Linear regression was calculated after inclusion
of potential co-variants. Non-significant co-variants were subsequently excluded, leaving APN and CD3+ as contributors within the most effi-
cient model. The multiplicative term (correlation x standardized b ×100) explains the variation of CD3diff illustrated by the respective par-
ameter in percent. (C) APN plasma concentrations in DCMi patients at inclusion into the study (DCMi 1) and at 6 month follow-up (DCMi 2).
Values are expressed as Mean+ SD. (D) APN and cardiac mononuclear infiltration at inclusion and at 6 month follow-up. APN concentrations
were measured by ELISA, CD3+ cells were determined by immunohistological staining.
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mirrors mechanistic aspects of human DCMi in mice. Groups of
mice were immunized with either a heart-specific alpha myosin
heavy chain peptide together with the adjuvant CFA or with
CFA only. In line with the human data, APN plasma concentrations
were significantly higher in mice with EAM, compared with
controls immunized with CFA only (5.9+ 0.6 vs. 7.4+ 0.6 mg/
mL, P,0.01, n ¼ 6). Furthermore, cardiac expression of APN as
well as APN receptor 1/2 was significantly increased in EAM
mice (Figure 4A and B), demonstrating enhanced APN signalling.
Those data implicate the inflammatory process in the regulation
Figure 4 Adiponectin (APN) gene transfer results in downregulation of multiple inflammatory mediators upregulated in murine autoimmune
myocarditis. (A) APN plasma concentration in mice with experimental autoimmune myocarditis (EAM). Three weeks after induction of EAM,
blood was drawn and APN concentrations were determined. Values are presented as mean+ SD (n ¼ 6 in each group), *P, 0.05 control vs.
EAM. (B) Cardiac APN signalling is increased in EAM. mRNA expression of APN and its receptors (APN receptor 1/2) were determined in
hearts of mice 3 weeks after EAM expression. Values are mean+ SD (n ¼ 6 animals in each group, *P, 0.05, **P, 0.01 control vs.
EAM). (C) Mouse chemokine and -receptors PCR array depicting change in expression of 84 genes in EAM. At 3 weeks following immunization,
RNA was extracted from hearts and gene expression measured. Thirty-two genes were upregulated and none was downregulated in EAM. APN
gene transfer caused a downregulation of 22 genes. 3D profiles and scatter blots are depicted for experimental groups as indicated. (D) APN
gene transfer significantly reduces cardiac levels of chemokines and its receptors involved in the pathogenesis of murine autoimmune myocar-
ditis. (E) APN gene transfer inhibits cardiac upregulation of pro-inflammatory cytokines in EAM determined by QRT–PCR.
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of APN expression. To test the hypothesis that APN acts as an
endogenous anti-inflammatory protein, groups of mice were
either transduced with an adenoviral vector, expressing mouse
APN, or a vehicle before immunization with CFA/MyHC-a.
Three weeks later, heart tissue was analysed for cytokine and che-
mokine expression using PCR array. Experimental autoimmune
myocarditis induction was associated with significant upregulation
of multiple inflammatory markers. Several cytokines, reflecting
active cardiac inflammation, such as TNFa, IFNg, IL-4, and IL-17
as well as chemokines, and their receptors were strongly upregu-
lated (Figure 4C–E). Remarkably, APN gene transfer caused down-
regulation of multiple chemokines and cytokines, including TNFa
and IL-17, well known to play a central role in the persistence
and progression of EAM (Figure 4E). In line with the observed
Figure 4 (Continued)
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downregulation of several inflammatory key cytokines, APN mice
had up to five-fold lower expression of the type 1 chemokine
receptor CXCR3 and its ligands CXCL9/CXCL11 (Figure 4D).
Interestingly, strong downregulation of both CCR2 and CCR5,
which have been shown to be crucial in EAM,27 was also observed.
Taken together, these data indicate a potent anti-inflammatory
effect of APN in inflammatory heart disease.
Adiponectin inhibits inflammation in
cardiomyocytes in vitro
Adiponectin has been shown to possess immunomodulating and
anti-inflammatory effects. Inflammatory cardiomyopathy is associ-
ated with increased TNFa signalling via its downstream target
NFkB. Similarly, TNF-alpha signalling is critically required for the
Figure 5 Adiponectin (APN) inhibits the inflammatory response in cardiac cells in vitro. (A) Soluble TNF-receptor 1 (sTNFR1) was measured
by ELISA in plasma samples of patients. Box plot illustrates elevated sTNFR1 in inflammatory cardiomyopathy (n ¼ 173) indicating augmented
TNFa-signalling compared with control (n ¼ 30). (B) APN inhibits TNFa-induced NFkB activation in vitro: neonatal rat ventricular myocytes
(NRVM) (left) and neonatal rat fibroblasts (right) were isolated, cultured, and incubated with TNFa for 30 min in the presence or absence
of APN and an NFkB inhibitor, BAY-11-7082 (20 mM). Cells were then harvested and whole cell lysates were used for the determination
of NFkB activity by ELISA. Values are expressed as mean+ SD for three independent experiments performed in triplicates (*P, 0.05,
**P, 0.01). (C ) APN inhibits production of reactive oxygen species: NRVM were isolated and incubated with H2O2. Fluorescence intensity
was measured (RFU, relative fluorescence intensity). Data for different time points are expressed as mean+ SD for three independent exper-
iments performed in triplicate (*P, 0.05, **P, 0.01).
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induction and progression of EAM.28 In our study population,
patients with DCMi exhibited significantly elevated sTNFR-1
serum concentrations (DCMi vs. control: 1533+448 vs.
1098+ 321 pg/mL, P, 0.001), a marker for activated TNFa sig-
nalling (Figure 5A). In order to further elucidate the effects of
APN on TNFa signal transduction within the myocardium, we per-
formed in vitro cell culture experiments. Following TNFa stimu-
lation, APN inhibited the activation of NFkB, a master
transcription factor activated in inflammation, in NRVM as well
as in neonatal rat fibroblasts in vitro (P, 0.05, Figure 5B). These
data implicate an anti-inflammatory effect of APN. Increased
redox stress has been implicated in DCMi progression and heart
failure. Accordingly, we analysed the effect of APN on the pro-
duction of ROS in cardiac myocytes. Production of ROS was sig-
nificantly diminished in cardiac myocytes following H2O2
incubation in the presence of APN (P, 0.01) (Figure 5C). Taken
together, our data implicate that inhibition of NFkB activation by
APN as well as a reduction of ROS generation as possible protec-
tive mechanisms in DCMi patients.
Adiponectin inhibits antigen specific T
cell responses in vitro
Adiponectin inhibits monocyte function in vitro including cytokine
expression and phagocytosis. However, very little is known
about the effect of APN on T cells, which play a critical role in
DCMi progression. In fact, mononuclear infiltrates in myocardial
tissue have been recently shown to be an independent positive
predictor for clinical outcome of patients with inflammatory cardi-
omyopathy.11 In our study, high baseline APN expression was
associated with lower CD3 infiltrates at follow-up. To investigate
a potential direct effect of APN on T cell expansion, we therefore
analysed the influence of APN on the generation of antigen-specific
T cell responses in vitro. Since it is difficult to raise specific human T
cell lines against myocardial antigens, the influence of APN on the
generation of influenza and EBV-specific T cells was analysed.
PBMCs were stimulated with antigens and expanded in vitro for
10 days. Adiponectin pre-incubation resulted in significant lower
numbers of influenza-specific (P, 0.01) as well as EBV-specific
(P, 0.05) IFNg, TNFa, and IL-2 producing T cells (Figure 6).
Taken together, these data indicate that APN inhibits expansion
of antigen specific T cells and might therefore be involved in a
negative feedback mechanism confining overhelming T cell
responses and chronic inflammation.
Discussion
This study elucidated the effects of APN in inflammatory cardio-
myopathy. We demonstrate, for the first time, that enhanced
APN expression parallels cardiac and systemic inflammation in
patients with DCMi. However, patients with high APN showed
decreased inflammatory cell infiltrates in their myocardium,
improved haemodynamics, and decrease NT-proBNP levels on
follow-up when compared with those with low APN levels.
These data suggest a regulatory role of APN in DCMi. Mice with
EAM also exhibited increased APN expression at the peak of
inflammation, and APN overexpression significantly inhibited the
upregulation of key chemokines/chemokine receptors and
pro-inflammatory cytokines known to mediate disease progression
in this model of human DCMi. In vitro, APN inhibited
NFkB-signalling in cardiomyocytes as well as expansion of antigen-
specific human T cells. Our data therefore implicate a novel
function of APN as anti-inflammatory cytokine confining cardiac
inflammation and disease progression in DCMi.
Human DCMi is characterized by mononuclear myocardial
inflammatory infiltrates and commonly results from infections
with cardiotropic viruses.29,30 Recent studies indicate that dilated
cardiomyopathy develops as late sequelae of chronic myocarditis
because of viral persistence or a chronic immune process initially
Figure 6 Adiponectin (APN) inhibits expansion of antigen-specific T cells. T cells in peripheral blood mononuclear cell samples were stimu-
lated with influenza or EBV or irrelevant HIV peptides in the presence of IL-2 and IL-7 with or without APN. At Day 10, numbers of antigen-
specific T cells were determined by cytokine production by flow cytometry. Six independent experiments using different donors are shown
(P, 0.05 for EBV, P, 0.01 for Influenza responses, respectively).
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triggered by viral infection.21,29 Chronic inflammation is frequently
followed by heart-specific autoimmunity.31,32 A breakdown in the
control mechanisms protecting against autoimmune reactions by
both presentation of normally not accessible self-antigens and
bystander-activation, induced by the pathogen, leads to the for-
mation of auto- reactive antibodies and T cells.33,34 In this
regard, a recent observational study by Kindermann et al.11
demonstrated that immunohistological signs of inflammation
rather than viral infection per se predict outcome of patients
with myocarditis and cardiac dysfunction.11 Thus, our current
mechanistic concept emanates from the assumption that an initially
beneficial cardiac immune response will become deleterious if
control and final resolution of the immune response is disturbed.
Here we show that plasma APN correlates with systemic
markers of inflammation (i.e., IL-8, sTNFR1, C-reactive protein)
and plasma as well as cardiac APN with myocardial mononuclear
infiltrates (i.e., CD3, CD45R0, Mac-1, LFA-1) in patients with
DCMi at baseline. This is consistent with elevated plasma levels
of the adipocytokine in other inflammatory states—such as lupus
erythematosus, rheumatoid arthritis, or inflammatory bowel
disease.14 In contrast to downregulation of local cardiac APN
expression in DCM,2 cardiac expression of APN in patients with
cardiac inflammation (DCMi) was significantly upregulated
suggesting the inflammatory process in the regulation of APN
expression. The mechanism for enhanced APN expression,
however, remains elusive, but appears to be independent of
TNFa signalling, known as a negative regulator of APN, since
sTNFR1 was enhanced in our patient population. Data obtained
in mouse EAM corroborate these findings, since cardiac infiltrates
were associated with high plasma and cardiac APN. Therefore, it is
tempting to speculate that the organ-specific inflammatory process
by itself upregulates APN expression as suggested by upregulation
of cardiac expression of APN and its receptors in EAM mice and
DCMi patients.
Previous studies characterized APN as immunomodulatory
bifunctional cytokine exerting both pro-inflammatory and anti-
inflammatory effects. In vitro, the induction of proinflammatory
cytokines by APN has mainly been studied in unstimulated cells,
whereas the induction of anti-inflammatory cytokines and attenu-
ation of adhesion and phagocytosis have mostly been observed
in stimulated cells. Extrapolating to the in vivo situation, it is poss-
ible that in an inflammatory milieu, APN mitigates inflammation. In
line with this, DCMi patients with high APN serum levels in our
study exhibited a significant decrease in myocardial mononuclear
infiltration at 6-month follow-up. Low cardiac infiltration was
associated with favourable outcome, an observation not found in
DCM patients. Thus, one may speculate that high APN levels,
although initially associated with enhanced cardiac inflammation,
may exert a long-term anti-inflammatory effect. In fact, our multi-
variate analysis revealed that APN explains 18% of the variability
of CD3 counts at follow-up. This hypothesis is supported by our in
vivo data from the EAM model. In fact, APN gene transfer resulted
in diminished RNA expression of various inflammatory molecules
in mice with EAM. Most interestingly, IL-17 was found to be down-
regulated playing a central role in EAM progression by promoting
recruitment of CD11b+ monocytes, the major heart-infiltrating
cells.35 In line with this finding, both CCR2 and CCR5, which
were shown to mediate migration of CD11b+ monocytes in
EAM, were diminished in APN vector transfected mice as well.27
Importantly, Day 21 reflects the peak of inflammation in the
EAM model. As expected, and in line with the observations in
the patients at baseline, APN levels are elevated at this time
point. Further long-term experiments including serial cardiac mor-
phological and functional investigations will be required to compre-
hensively characterize all APN actions in the EAM model, i.e.
effects on cardiomyopathy phenotype. Nevertheless, our data
already strongly support the contention that endogenously
released APN acts as protective cytokine downregulating the
inflammatory process in DCMi. To further study the potential
effect of APN on the antigen-specific T cell responses, we per-
formed in vitro studies. In line with our concept, we could
observe that APN exerts an inhibitory effect on the expansion
of anti-viral memory and effector T cell responses in vitro.
Our findings are in accordance with previous studies of the role
of APN in inflammatory models. Reduced APN expression in
cyclooxygenase-2 deficient mice was associated with enhanced
inflammatory cell damage in a model of EMC virus-induced myo-
carditis.36 Moreover, inflammatory myocardial damage was attenu-
ated in leptin-deficient mice with viral myocarditis following APN
replacement therapy.18 Furthermore, induction of cardiac APN
expression by candesartan diminished cardiac damage in obese
mice with viral myocarditis37 and improved survival.38 Taken
together, our data complete other studies pointing to an anti-
inflammatory and cardioprotective role of APN in inflammatory
cardiomyopathy.
Our in vitro experiments also implicate direct anti-inflammatory
effects of APN in cardiac myocytes and fibroblasts both showing
diminished NFkB activation after TNFa stimulation. TNFa
depresses cardiac contractility, induces cardiomyocyte apoptosis,
activates the inflammatory response,39 and induces dilated
cardiomyopathy.40,41 Therefore, TNFa, upregulated in patients
with DCMi in our study as assessed by sTNFR1, might be a key
mediator in the development of heart failure. NFkB is an
important transcription factor mediating the detrimental and
pro-inflammatory effects of TNFa, and abrogation of NFkB in
TNFa transgenic mice improved survival and severity of DCM.42
Therefore, inactivation of NFkB, a central transcription factor in
driving the inflammatory and remodelling response downstream
of TNFa, might diminish endomyocardial inflammation and reor-
ganization of cell–matrix interactions. In fact, NFkB has direct
effects on apoptosis, calcium handling, cell adhesion, and
expression of inflammatory proteins (i.e., COX2, iNOS). Recently,
NFkB induction has been demonstrated in the failing human
heart.43,44 Moreover, silencing of NFkB prevented heart failure
and hypertrophy in mouse models of pressure overload as well
as after coronary artery ligation.45 In this regard, APN knockout
mice showed higher mortality and larger LVEDD in a pressure
overload model.46 Taken together, APN might diminish the inflam-
matory response as well as left ventricular remodelling also by
direct inhibition of NFkB activation in cardiac myocytes and
fibroblasts.
In conclusion, our data point to a novel anti-inflammatory role of
APN in human inflammatory heart disease and suggest to explore
APN as a novel therapeutic concept.
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pericardial tamponade in a stubbed patient
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A 27-year-old drug-abuser presented
with tachypnoea, sinus tachycardia, and
hypotension (systolic blood pressure
86 mmHg). He had been stubbed with
.20 table-knife punctures at his left axil-
lary area (Panel A) at a street brawl 1 h
before. His jugular veins were promi-
nent, he had pulsus paradoxus, and
86% O2 saturation at blood gases. He
was not bleeding externally. Immediate
echocardiogram revealed pericardial
fluid, probably haemopericardium, with
signs of tamponade (mitral inflow
Doppler velocities, Panel B). On emer-
gent contrast CT scan of the thorax, a
large left haemothorax, haemopericar-
dium of at least moderate degree along
with pericardial tearing and pneumoper-
icardium, and subcutaneous emphysema
were seen (Panels C and D). The patient’s
condition was deteriorating. Neither a
thoracic nor a cardiothoracic surgeon
was available by that time. Fearing the
creation of a bleeding conduit between
the pericardial space and the drainage system if pericardiocentesis was performed, it was decided first to place a Billow-tube at his
left hemithorax. Surprisingly, soon after the procedure, his vital signs improved markedly and his condition gradually recovered. Intu-
bation was avoided. A new CT scan, performed 4 h later without contrast, confirmed a significant drainage of both the pericardial and
the pleuritic haematomas (Panel E). He was given antibiotics and was transfused with two units of blood. Myocardial or coronary
laceration, if any, passed by clinically undetectable. Troponin peaked at 4.3 ng/L. He has had an uncomplicated course since then.
Our patient was lucky to survive because the pericardial blood drained into the pleuritic cavity through the artificial pleuropericardial
window that had been created by the knife. More so, he was fortunate not to bleed any more despite pleurocentesis, due to spon-
taneous haemostasis. Pericardiocentesis for acute haemopericardium sets always a problem for caring physicians.
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